LAVA Therapeutics N.V.
Stock Forecast, Prediction & Price Target
LAVA Therapeutics N.V. Financial Estimates
LAVA Therapeutics N.V. Revenue Estimates
LAVA Therapeutics N.V. EBITDA Estimates
LAVA Therapeutics N.V. Earnings per Share Estimates
| Passed | Analyst forecast | ||||||
|---|---|---|---|---|---|---|---|
| Metric | 12/31/2021 | 12/31/2022 | 12/31/2023 | 12/31/2025 | 12/31/2026 | 12/31/2027 | 12/31/2028 |
Revenue
% change YoY
| $5M N/A | $19.39M 287.82% | $6.76M -65.09% | Avg: $9.04M Low: $9.04M High: $9.04M avg. 33.69% | Avg: $10.46M Low: $10.46M High: $10.46M avg. 15.62% | Avg: $3.59M Low: $3.59M High: $3.59M avg. -65.68% | Avg: $33.36M Low: $33.36M High: $33.36M avg. 829.13% |
Net Income
% change YoY
| $-45.34M N/A | $-31.90M 29.63% | $-41.97M -31.55% | Avg: $-50.01M Low: $-56.86M High: $-36.55M avg. -19.14% | Avg: $-63.49M Low: $-53.61M High: $-36.05M avg. -26.95% | Avg: $-35.29M Low: $-35.29M High: $-35.29M avg. 44.40% | Avg: $-26.13M Low: $-26.13M High: $-26.13M avg. 25.95% |
EBITDA
% change YoY
| $-44.35M N/A | $-33.71M 23.97% | $-40.41M -19.86% | Avg: $-5.42M Low: $-5.42M High: $-5.42M avg. 86.56% | Avg: $-6.27M Low: $-6.27M High: $-6.27M avg. -15.62% | Avg: $-2.15M Low: $-2.15M High: $-2.15M avg. 65.68% | Avg: $-20.01M Low: $-20.01M High: $-20.01M avg. -829.13% |
EPS
% change YoY
| -$2.3 N/A | -$1.23 46.52% | -$1.57 -27.64% | Avg: -$1.62 Low: -$2.13 High: -$1.37 avg. -3.21% | Avg: -$1.57 Low: -$2.01 High: -$1.35 avg. 3.13% | Avg: -$1.32 Low: -$1.32 High: -$1.32 avg. 15.88% | Avg: -$0.98 Low: -$0.98 High: -$0.98 avg. 25.95% |
Operating Expenses
% change YoY
| $49.35M N/A | $54.22M 9.87% | $46.54M -14.17% | Avg: $12.26M Low: $12.26M High: $12.26M avg. -73.64% | Avg: $14.18M Low: $14.18M High: $14.18M avg. 15.62% | Avg: $4.86M Low: $4.86M High: $4.86M avg. -65.68% | Avg: $45.21M Low: $45.21M High: $45.21M avg. 829.13% |
FAQ
What is LAVA Therapeutics N.V. stock earnings growth forecast?
Wall Street analysts estimate the annual average earnings growth rate of 6.06% in 2025-2028.
We have gathered data from 3 analysts. Their low estimate is -56.86M, average is -50.01M and high is -36.55M.
What is LAVA Therapeutics N.V. stock revenue growth forecast?
Wall Street analysts forecast annual average revenue growth of 203.19% in 2025-2028.
We have gathered data from 4 analysts. Their low revenue estimate is $9.04M, average is $9.04M and high is $9.04M.
What is LAVA Therapeutics N.V. stock earnings per share growth forecast?
Wall Street analysts forecast annual average earnings growth of 10.43% in 2025-2028.
We have gathered data from 3 analysts. Their low earnings per share estimate is -$2.13, average is -$1.62 and high is $-1.36.
What is the best performing analyst?
In the last twelve months analysts have been covering LAVA Therapeutics N.V. stock. The most successful analyst is Arthur He.